Piper Jaffray analyst Danielle Brill thinks there is a "substantial amount of evidence" that shows clear proof-of-efficacy of GlycoMimetics' rivipansel in the sickle cell disease population. As such, the analyst remains confident that the Phase 3 data expected this quarter will be positive. The stock's risk/reward is "highly favorable," with 70%-100% upside versus downside of 20%-25% on the readout, making GlycoMimetics "even more compelling ahead of the data," Brill tells investors in a research note. She reiterates an Overweight rating on the shares with a $20 price target.